Business Context and Reporting Period
Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1999
Business Overview: The Company provides laboratory testing services. As of July 31, 1999, Roche Holding Ltd. indirectly held approximately 48% of the common stock and a significant portion of the warrants.
Key Financial Metrics
All figures in millions of dollars, except per share data.
| Metric | Three Months Ended June 30, 1999 | Six Months Ended June 30, 1999 |
|---|---|---|
| Net Sales | $429.5 | $847.4 |
| Gross Profit | $164.3 | $315.7 |
| Operating Income | $42.1 | $76.5 |
| Net Earnings | $19.8 | $34.0 |
| Net Earnings Attributable to Common Shareholders | $7.1 | $10.0 |
| Diluted EPS (Common) | $0.06 | $0.08 |
| Cash and Cash Equivalents (Balance Sheet) | $16.9 (as of June 30, 1999) | |
| Net Cash Provided by Operating Activities | $75.9 (Six Months) | |
| Total Debt (Current + Long-Term) | $595.7 (Current: $66.8; Long-Term: $528.9) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.7% for the quarter and 7.2% for the six-month period compared to 1998. Growth was driven by a 2.3% price increase and 4.4% volume increase in the quarter.
- Profitability: Net earnings attributable to common shareholders improved significantly from a loss of $0.6 million in the six-month period of 1998 to a profit of $10.0 million in 1999.
- Cost Management: Cost of sales as a percentage of net sales decreased from 64.1% to 61.7% (quarter) and 65.0% to 62.7% (six months) due to cost reduction efforts.
- Bad Debt Expense: Selling, general, and administrative (SG&A) expenses increased primarily due to a $10.9 million rise in bad debt expense for the quarter (and $23.0 million for six months), attributed to payment delays from large managed care and hospital payors.
- Interest Expense: Net interest expense decreased by $1.7 million for the quarter and $3.9 million for the six months, resulting from lower interest rates, debt reduction, and favorable credit agreement amendments.
- Tax Provision: The effective tax rate decreased from 49.6% to 38.0% (quarter) due to a reduction in the valuation allowance on deferred tax assets.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects cash on hand, operating cash flows, and borrowing capabilities under the Amended Revolving Credit Facility to be sufficient for operations, capital expenditures, and potential acquisitions.
- Days Sales Outstanding (DSO): DSO improved to 79 days from 83 days in the prior quarter. The Company is implementing a centralized billing system to further reduce DSO, with substantial conversion expected by the end of 2000.
- Year 2000 (Y2K) Compliance: The Company estimates total Y2K expenditures between $20.0 million and $25.0 million. Remediation for business-critical systems is scheduled for completion by September 30, 1999. Management notes that failure of third-party suppliers to achieve compliance could adversely affect operations.
- Legal Proceedings: The Company faces class action litigation regarding private reimbursement claims similar to a 196 Government Settlement. No damages have been specified, and the outcome is currently unpredictable. Management believes other ordinary course legal matters will not have a material adverse effect.
- Debt Covenants: A Third Amendment to the Credit Agreement became effective in May 1999, addressing leverage ratios and Y2K issues, and allowing for limited preferred stock purchases.
Investor Verification Checklist
- Bad Debt Trends: Verify the sustainability of the increase in bad debt expense and the effectiveness of the new centralized billing system in reducing DSO.
- Preferred Stock Obligations: Review the impact of mandatory preferred stock dividends ($23.5 million for six months) on cash available to common shareholders.
- Y2K Execution: Monitor the completion of Y2K remediation and testing schedules to ensure no operational disruptions occur at the turn of the millennium.
- Legal Exposure: Track developments in the class action litigation regarding private reimbursement claims for potential future liabilities.
- Debt Structure: Confirm adherence to the new leverage ratio requirements under the amended credit agreement.